CD19 and graft versus host disease: Although it is well known that haploidentical HSCT generally shows profound and prolonged immune incompetence because of aggressive GvHD prophylaxis [27, 28], our center applies the TCRαβ T-cell/CD19+ depletion approach for all haploidentical HSCT, without the use of immunosuppressive agents for GvHD prophylaxis and CMV prophylaxis following HSCT.